Importantly, the in vitro potency of HOSU-53 (0.95 nM IC50 in cell-free human DHODH inhibition assay) was comparable to BAY2402234 (0.97 nM), superior to six other DHODH inhibitors evaluated, and it showed prolonged survival benefits in the MOLM-13 cell line–derived xenograft disseminated AML mice model when combined with other front-line therapies [22]. Here, DHODH is linked to acute myeloid leukemia.